University of New Mexico

UNM Digital Repository
Biomedical Engineering ETDs

Engineering ETDs

Summer 7-17-2017

Assessing the utility of phenylene ethynylenes
against Candida species pathogens
Rina Sylejmani
University of New Mexico

Follow this and additional works at: https://digitalrepository.unm.edu/bme_etds
Part of the Other Medicine and Health Sciences Commons
Recommended Citation
Sylejmani, Rina. "Assessing the utility of phenylene ethynylenes against Candida species pathogens." (2017).
https://digitalrepository.unm.edu/bme_etds/14

This Thesis is brought to you for free and open access by the Engineering ETDs at UNM Digital Repository. It has been accepted for inclusion in
Biomedical Engineering ETDs by an authorized administrator of UNM Digital Repository. For more information, please contact disc@unm.edu.

Rina Sylejmani
Candidate

Biomedical Engineering
Department

This thesis is approved, and it is acceptable in quality and form for publication:
Approved by the Thesis Committee:
Aaron K. Neumann
David G. Whitten
Eva Y. Chi

, Chairperson

Assessing the utility of phenylene ethynylenes against
Candida species pathogens
By
Rina Sylejmani
B.S. Chemistry, University of New Mexico, 2015
B.S. Biology, University of New Mexico, 2015

THESIS
Submitted in Partial Fulfillment of the
Requirements for the Degree of
Master of Science
Biomedical Engineering
The University of New Mexico
Albuquerque, NM
July 2017

i

DEDICATION
This thesis is dedicated to my family, especially my dad,
the first and best engineer I know.

ii

ACKNOWLEDGMENTS
I take great pride and gratitude in being part of the Neumann Research Group throughout
the duration of my graduate studies. I want to express many thanks to my graduate
advisor and chair, Dr. Aaron Neumann, for continuously showing me what it means to
practice sound science. From his countless advice and ideas, he has been the epitome
of a great scientist, and I hope to emulate the same passion he brings to his work in my
future endeavors. I would like to extend my appreciation to the members of my committee
of studies: Dr. David Whitten and Dr. Eva Chi. Their continuous guidance has been
fundamental in the completion of my project and I will always remember their invaluable
support. I would also like to thank Dr. Thomas Howdieshell for his input throughout the
duration of this project.
Additionally, I want to thank Dr. Harry Pappas for his unwavering mentorship.
Thank you to all the members of the Neumann lab for their assistance. I want to to give a
special thanks to Carmen Martinez and Eddy Anaya, for their friendship, help and
stimulating discussion when the science did not cooperate. I am grateful to the University
of New Mexico for the opportunities and resources they have provided me to improve
scholastically. I want to thank the numerous friends I have made as part of this program
for always being willing to troubleshot and teach me new methods – Adrian Luna, Jason
Joyner, Sebastian Restrepo Cruz, and Florencia Monge.
Lastly, when it comes to acknowledging those that are most instrumental to my
success, my family deserves insurmountable thanks. As war refugees, my parents have
made great sacrifices and taught me to value my education. My siblings – Gresa, Dijar
and Donart have been the best support system. They provide relentless laughs and
advice in the most stressful of times and their kindness will always be cherished.

iii

Assessing the utility of phenylene ethynylenes against
Candida species pathogens
By
Rina Sylejmani
B.S. Chemistry, University of New Mexico, 2015
B.S. Biology, University of New Mexico, 2015
M.S. Biomedical Engineering, University of New Mexico, 2017
ABSTRACT
Candida species are the cause of many bloodstream infections through contamination of
indwelling medical devices. These infections account for a 40% mortality rate, posing a
significant risk to immunocompromised patients. Traditional treatments against Candida
infections include amphotericin B and various azole treatments. Unfortunately, these
treatments are associated with high toxicity, and resistant strains have become more
prevalent. As a new frontier, light-activated phenylene ethynylenes have shown promising
biocidal activity against Gram-positive and -negative bacterial pathogens, as well as the
environmental yeast, Saccharomyces cerevisiae. In this thesis, we monitored the viability
of Candida species after treatment with a cationic conjugated polymer (PPE) or oligomer
(OPE) by flow cytometry in order to explore the antifungal properties of these compounds.
The oligomer was found to disrupt Candida albicans yeast membrane integrity
independent of light-activation, while the PPE is only able to do so in the presence of light,
allowing for some control as to the manner which cytotoxic effects are exhibited.
Furthermore, treatment with PPE-DABCO unmasked Candida albicans β-glucan, and
increased phagocytosis by Dectin-1-expressing HEK-293 cells. Additionally OPE
exhibited potent antifungal activity against Candida albicans and Candida parapsilosis,
two medically significant fungal pathogens. In contrast, another major Candida species
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pathogen, Candida glabrata, displayed intrinsically low susceptibility to OPE, relative to
C. ablicans and C. parapsilosis. In C. glabrata, the primary mechanism of azoleresistance is attributed to alterations in the ERG11 gene and over-expression of the
CgCDR1 efflux pump gene. We hypothesize that similar mechanisms may account for C.
glabrata resistance to OPE. We monitored the susceptibility of C. glabrata to OPE by
flow cytometry after treatment with clorgyline, a broad spectrum efflux pump inhibitor.
Clorgyline showed synergy with OPE in type strain ATCC2001. In summary, cationic
phenylene ethynylenes show promising biocidal activity against pathogenic Candida spp.
alone and in combination with clorgyline.
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Chapter 1
Introduction
1.1 Significance
In modern medicine, systemic candidiasis remains a pertinent healthcare problem. While
immunocompromised patients are most at risk for these infections; increased microbial
access to the bloodstream in burn victims and during invasive surgical procedures pose
subsequent risk to immune competent patients. Annually, the United States spends
millions of health care dollars in the diagnosis and treatment of these infections (1, 2)
More importantly, bloodstream infections cause ~ 31,000 mortalities yearly. Candida
species are the fourth leading cause of all bloodstream infections and account for a 40%
mortality rate (1, 3, 4). The most commonly isolated species of infection is C. albicans,
but the prevalence of other species such as C. parapsilosis and C. glabrata is increasing
(5–7) . Present antifungal treatment to combat these infections include azoles,
echinocandins, and polyenes. However, these traditional treatments are often associated
with the rise of resistant strains and cytotoxic effects (8, 9) . The high morbidity and
mortality rates associated with systemic candidiasis elicit an urgent demand for novel
antifungal therapies.
1.2 Poly(phenylene ethynylene)
Light-activated poly(phenylene ethynylenes) (PPEs) have shown promising biocidal
activity against Gram-positive and -negative bacterial pathogens, as well as the
environmental yeast, Saccharomyces cerevisiae (10–14) . In addition to their promising
antimicrobial activity, they exhibit low toxicity to human cells in vitro (15). The purpose of
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this thesis aims to test the utility of these compounds against a range of Candida species
pathogens and assess the potential for resistance. The experiments described explored
the antimicrobial activity of two particular phenylene ethynylene compounds, PPEDABCO and EO-PPE-DABCO. The antimicrobial activity of poly(phenylene ethynylene)
compounds such as PPE-DABCO and EO-PPE-DABCO can be attributed to several
intrinsic characteristics.

The chemical structure of these compounds renders them

capable of inducing broad-spectrum cell damage. The phenylene ethynylenes studied
consist of alternating phenyl and acetylenic groups with appended cationic groups (Fig.
1).

Figure 1: Molecular structures of oligomeric EO-OPE-DABCO (top) and polymeric PPEDABCO (bottom).

The interaction of the cationic quaternary ammonium groups with net-anionic membranes
and cell walls facilitates interactions with microbes, leading to membrane perturbation,
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pore formation, and the leakage of cell contents (16). In addition, when PEs are irradiated
by the appropriate wavelength, the backbone produces reactive oxygen species (ROS)
that induce rapid cell death (17, 18).
1.3 Drug resistance in Candida glabrata
While C. ablicans is most commonly isolated species of bloodstream and mucosal
candidiasis, C.glabrata poses a significant threat because of its intrinsic resistance to the
commonly prescribed antifungal known as fluconazole (19, 20). Fluconazole targets the
ergosterol biosynthetic pathway in fungi. C. glabrata is not only intrinsically resistant to
fluconazole but resistance has been observed to increase during treatment (21, 22). The
reduced efficacy of fluconazole against C. glabrata has been largely attributed to
alternations in the target enzyme, ERG11, consequently reducing the effect of the drug.
Additionally drug resistance is mediated by drug efflux pumps, specifically, the increased
expression of ABC transporters known as CgCdr1, CgCdr2 (Pdh1), and CgSnq2 (23, 24).
These transporters serve to transport substances across the membrane and are found
primarily in the plasma membrane and also in the membranes of organelles . In C.
glabrata, overexpression of proteins that pump drug out the cell has been correlated with
high-level azole resistance (25, 26) . Animal studies have shown that strains with
hyperactive C. glabrata PDR1 (CgPDR1) alleles that upregulate CgCDR1, CgCDR2,and
CgSNQ2 expression were more virulent in mice than strains with wild-type alleles (27).
The testing of new antifungals against C. glabrata requires careful consideration in
overcoming efflux mediated drug resistance.
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Chapter 2
The Antifungal Properties of Cationic Phenylene Ethynylenes and their Impact on
β-Glucan Exposure
2.1 Introduction
Bloodstream infections affect a huge patient population in the United States, with more
than 250,000 cases reported each year (1). Patients with indwelling medical devices,
such as central venous catheters (CVCs), are most at risk for these infections (2).
Frequently, various microorganisms from the skin of the patient, or respective healthcare
professional, can gain access through the catheter wound as a result of non-sterile
conditions (3–6). Of these resulting bloodstream infections, Candida species account for
9% of all instances and are associated with a ~40% mortality rate (2, 7). The most
commonly isolated fungal pathogen from bloodstream infections is Candida albicans, but
the prevalence of other species, such as C. parapsilosis, C. glabrata, and C. tropicalis, is
increasing (8, 9).
An important determinant of pathogenicity among Candida spp. is the outer cell
wall. The cell wall is primarily composed of carbohydrates and, structurally, is separated
into two layers. The outer layer is composed mostly of cell wall glycoproteins with N- and
O-linked mannans, and the inner layer is composed of β-glucan and chitin.

The

complexity of the cell wall contributes to various pathogenic factors including adherence
of the fungus and establishment of cross-talk with the host known as “glycan code” (10–
12).

Cell wall components, such as β-glucan and other polysaccharides, are also found

in the extracellular matrix secreted by Candida spp. biofilms, which can contaminate the
synthetic material surfaces of indwelling medical devices. β-glucan in the extracellular
matrix of Candida biofilms has been shown to sequester antifungal drugs, which
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contributes to decreased drug susceptibility of biofilms (13–15).
Various antimicrobial impregnation approaches have been devised to prevent
catheter infections. Catheter materials coated with chlorhexidine-silver sulfadiazine and
minocycline/rifampin have shown trends in reduced infection rates, but their clinical
effectiveness remains questionable (16, 17). Other treatments, including the use of silverimpregnated subcutaneous collagen cuffs, have also shown to be ineffective in recent
trials (18, 19). CVC contamination generally requires device removal and replacement,
in addition to a prolonged course of antifungal drug therapy, which raises concerns
regarding drug toxicity and the development of antifungal resistance.

Antifungal

chemotherapy is also problematic, as many antifungal drugs are either toxic to the host
(amphotericin B), or result in drug-resistant strains (triazoles) (20). Due to the high
morbidity and mortality rate of catheter-related Candida spp. bloodstream infections,
strategies for preventing medical device contamination by fungal pathogens remain a top
priority for infection control.
In this study, we sought to elucidate the antimicrobial effectiveness of two pphenylene ethynylene (PE) compounds against Candida species. A subset of conjugated
polyelectrolyte, phenylene ethynylenes have shown promising biocidal activity against
Gram-positive and -negative bacterial pathogens, as well as the environmental yeast,
Saccharomyces cerevisiae (21–23). The chemical structure of these compounds renders
them capable of inducing broad-spectrum cell damage. The phenylene ethynylenes
studied consist of alternating phenyl and acetylenic groups with appended cationic groups
(Figure 1). The interaction of the cationic quaternary ammonium groups with net-anionic
membranes and cell walls facilitates interactions with microbes, leading to membrane
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perturbation, pore formation, and the leakage of cell contents (24). In addition, when PEs
are irradiated by the appropriate wavelength, the backbone produces reactive oxygen
species (ROS) that induce rapid cell death (25, 26).

Figure 2: Molecular structures of oligomeric EO-OPE-DABCO (top) and polymeric PPEDABCO (bottom).

In previous studies, the oligomeric and polymeric molecular size of PE compounds has
played an important role in their mechanisms of killing. The antimicrobial activity of these
compounds is dependent on various factors that include molecular conformation, size,
functional groups, and, of course, membrane composition of the target pathogen (22).
The studies described herein serve as a preliminary investigation into the utility of a
cationic conjugated polymer, poly(p-phenylene ethynylene) and oligomer, “end-only”
oligo(p-phenylene ethynylene) as antifungals. After treatment with the compounds—
hereby referred to as PPE-DABCO and EO-OPE-DABCO—the viability of Candida spp.
was monitored using flow cytometry. This novel class of compounds may provide an
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innovative approach to preventing catheter-related bloodstream infections caused by C.
albicans and other Candida species.
2.2 Materials & Methods
Fungal Culture
Candida albicans (ATCC, #MYA-2876), C. parapsilosis (ATCC, #22019), and C. glabrata
(ATCC, #2001) were grown from glycerol stocks, stored at -80 °C. Said stock was
transferred to 5 mL filter-sterilized yeast extract-peptone-dextrose (YPD) medium (Becton
Dickinson), and grown for 16 h at 30 °C, with a shaking speed of 300 RPM. Such growth
conditions yielded yeast at the late log phase (27).
Following a 10 minute centrifugation at 2,900 rcf, the supernatant was replaced
with sterile phosphate-buffered saline (PBS), and subsequently vortexed. This washing
step is repeated a second time to mitigate cell debris. Cell concentration was then
determined using a disposable hemocytometer (INCYTO C-Chip; Fisher Scientific).
Derivation of Clinical Isolate Strains of C. albicans
Patient specimens (peripheral blood or catheter tips) were processed by Tricore
Reference Laboratories (Albuquerque, NM) and identified as C. albicans using a Bruker
Biotyper MALDI-TOF system (MS ID score > 2.0). Clonal isolates so identified were
subcultured on Sabouraud agar slants and provided to the investigators as unique strains.
Isolate strains were provided in completely deidentified form according to procedures
approved by the University of New Mexico School of Medicine Human Research
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Protections Office. For biocidal assays, clinical isolates were grown in YPD broth as
described above.
Biocidal Testing
All biocidal experiments were carried out in either translucent or opaque 1.5 mL
microcentrifuge tubes, at cell concentrations of 5 x 106/mL. Two cationic compounds
were tested, both based on the p-phenylene ethynylene backbone, with quaternized
diazabicyclo[2,2,2]octane (DABCO)-functionalities. EO-OPE-DABCO and PPE-DABCO
stocks were prepared in sterile deionized water (18.2 MΩ·cm at 25 °C), and contained
0.47% dimethyl sulfoxide (by volume) to improve solubility and minimize aggregate
formation. Negative controls contained equal amounts of dimethyl sulfoxide.
Samples were exposed to controlled amounts of light using a 14-lamp photoreactor
(LZC-4V; Luzchem Research; Ottawa, Ontario). A rotating carousel ensured that all
samples receive equivalent levels of light exposure; ventilation kept the photoreactor
below 30 °C. EO-OPE-DABCO absorbs in the ultraviolet region (28), warranting the use
of UVA lamps (350 nm emission peak; 4.46 ± 2.41 mW/cm2) to optimize singlet oxygen
yields. Conversely, 420 nm blue-light lamps (6.62 ± 2.93 mW/cm2) were used in PPEDABCO tests; unlike its oligomeric counterpart, polymeric PPE-DABCO absorbs in the
near-visible range (29). Power density output was measured at the peak excitation
wavelength for both lighting configurations.

Data shown is an aggregation of two

independent replicate experiments.
Samples were then stained with 5 µM membrane-permeable SYTO 9 (Invitrogen,
S34854) and 1 µM membrane-impermeable TO-PRO-3 (Invitrogen, T3605), both of which
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are nucleic acid stains.

After 30 min, samples were evaluated by flow cytometry

(FACSCalibur; Becton Dickinson). At least 10,000 events were evaluated in each trial.
A heat-killed sample (70 °C for 30 min) was used to identify the fluorescence
characteristics of dead cells.
15 min dark-activity assays were carried out in a somewhat different manner.
Samples were prepared and stained with SYTO 9 and TO-PRO-3, albeit in the absence
of any biocide. After a 30 min staining duration, EO-OPE-DABCO was added (10 µg/mL
final concentration); the sample was then vortexed and analyzed by flow cytometry.
Every minute, viability data was collected (again, 10,000 events/sample), for a total of 15
minutes. It is important to note that EO-OPE-DABCO was added one sample at a time,
so that, in each case, flow cytometry readings could begin within 1 min of the biocide’s
introduction.
Spectroscopy of β-glucan Interactions
Stocks of S. cerevisiae β-(1,3)-glucan (high, medium or low MW; gift of Biothera, Eagan,
MN), PPE-DABCO, and EO-OPE-DABCO were mixed with 10 mM pH 7.4 phosphate
buffer to a final concentration of 2 µg/mL in PPE-DABCO or EO-OPE-DABCO and 100
µg/mL in β-glucan. 200 µL solutions were transferred to a 160 µL nominal volume fused
quartz fluorimetry cuvette, and read on a PTI QuantaMax 40 steady-state fluorescence
spectrophotometer (HORIBA Scientific, Edison, NJ) with PMT detection. Emission
spectra were obtained using an excitation wavelength of 350 nm for EO-OPE-DABCO
and 420 nm for PPE-DABCO, and excitation spectra were obtained with the
corresponding maximum emission wavelength.
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Interactions of PPE-DABCO with Glucan Microparticles
Glucan microparticles were prepared from Candida yeast cells using the extraction
techniques disclosed Lowman et al (30). Glucan microparticles were then suspended in
PBS at a concentration of 1 x 105 mL-1. Microparticles were sonicated for 10 min, and
subsequently vortexed for another 5 min.

PPE-DABCO was then added at a

concentration of 2 µg/mL, and incubated at room temperature for 1 h. No PPE-DABCO
was added to the negative control. 500 µL of each sample was transferred to petri dishes
for examination by confocal microscopy.

405 nm excitation was used to induce

fluorescence of PPE-DABCO.
Surface Exposure of β-glucan
C. albicans yeast cells were treated in a similar manner to that of the previously described
biocidal experiments. In effort to maintain a consistent degree of cell death across
samples, OPE-DABCO exposure in UVA light was limited to just 10 min. A thermal
positive control was also implemented, which entailed heating samples to 100 °C for 30
min. Following the appropriate treatment and removal from the photoreactor, samples
were blocked with 1% (w/v) bovine serum albumin (BSA) for 30 min at room temperature.
The samples were then treated with a primary antibody, anti β-glucan IgG (Biosupplies,
400-2), at a final concentration of 10 µg/mL, for an additional 30 min. Negative controls
contained 10 µg/mL isotype-matched murine IgG in place of anti β-glucan IgG.

A

secondary antibody with Alexa Fluor 647 dye (Invitrogen, A21235) was then added (1
µg/ml in PBS+1% BSA), along with 5 µM SYTO 9 were simultaneously added and allowed
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to stain cells for 30 minutes at 25 °C prior to analysis by flow cytometry. Data shown is
an aggregation of two independent replicate experiments.
Tissue Culture & Transfection
HEK-293 cells (ATCC, #CRL-1573) were cultured in DMEM supplemented with 10% CS,
1% Penicillin/Streptomycin, 2mM L-glutamine, and 1mM sodium pyruvate at 37°C, 5%
CO2. Cells were then plated in 6 well plate at 1x105 cell per well. mApple-human
Dectin1A-C-10 (gift of Michael Davidson, Addgene #54883) was transfected into cells by
following standard protocols using Fugene 6 (Promega, #E2691). Cell cultures were used
for further experimentation at 24 h post-transfection with growth in normal medium, as
described above.
Phagocytosis Assay
C. albicans yeast cells were subjected to the same treatment conditions as in the
aforementioned β-glucan exposure study, before being spun down and washed in PBS.
Following the last wash step the C. albicans were stained with 7.5μM of SYTO 9
(Invitrogen, #S-34854) and 75μM of CypHer5E NHS-ester (GE Healthcare, #PA15401)
for one hour at 25°C. After staining the C. albicans were added to live, Dectin-1A-C-10
transfected HEK-293 cells for one hour. Next ice cold PBS was used to lift the HEK-293
cells off of the plate. The controls with C. albicans or HEK-293 alone or the above
samples with a mixture of C. albicans and HEK-293 cells were analyzed using an LSR
Fortessa flow cytometer (Becton Dickinson) and FlowJo software (FlowJo, Ashland, OR).
At least 10,000 side scatter (SSC)-positive events are evaluated in each trial. CypHer 5,
SYTO 9, and mApple fluorescence was observed at emission wavelengths of 660 nm
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(670/14), 525 nm (505 LP, 530/30), and 578 nm (582/15), respectively. Data shown is an
aggregation of two independent replicate experiments.
2.3 Results
A series of biocidal studies were carried out to gain insight to the light-activated effects of
EO-OPE-DABCO and PPE-DABCO on Candida species pathogens.

Phenylene

ethynylenes are unique in that their mechanism of action differs, depending on the
presence of light; in particular, light intensity, emission wavelength, and duration (31). In
the studies described herein, duration of light exposure was the primary variable being
studied. Light intensity was kept constant using a photoreactor with 14 interchangeable
lamps. Lamps were chosen to have an emission wavelength overlapping the excitation
spectrum of the phenylene ethynylene being used. 350 nm-centered UVA lamps were
implemented for OPE testing, while 420 nm-centered lamps were used in PPE tests. With
light intensity and spectrum being held constant for a given phenylene ethynylene, we
focused on light exposure duration as the major focal point in an effort to discern C.
albicans’ susceptibility to phenylene ethynylenes in the light vs. dark. Even though all
samples were exposed to one of the two compounds for a total of 60 min, the duration of
light exposure was varied by 4 min intervals and the balance of 60 min exposure was in
the dark.
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Figure 3: C. albicans yeast viability as a function of light exposure duration and
antimicrobial concentration. Viability is shown on a logarithmic scale for EO-OPE-DABCO
(A) or PPE-DABCO (B) at 1 µg/ml (dashed lines) or 10 µg/ml (solid lines). Significant
differences in viability are indicated by filled data markers (P-value ≤ 0.01).
Fig. 2A illustrates the biocidal activity of the two concentrations of EO-OPE-DABCO: 1
and 10 µg/mL. In the absence of light, a 1 µg/mL concentration of OPE killed 34% of C.
albicans yeast cells; however, killing drastically increased with just minimal light exposure,
as 2 log cell death was observed after just 8 min. Increasing the concentration to 10
µg/mL greatly improved the dark killing capacity of the OPE, resulting in 97% cell death.
With minimal light exposure, 10 µg/mL EO-OPE-DABCO exhibited a profound biocidal
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effect, exceeding 3 log reduction after just 4 min in UVA light. Both OPE concentrations
exceeded 3 log kill (over 99.9% cell death) after 20 min of light exposure, and 4 log
reduction (99.99% cell death) is nearly achieved after 60 min of light exposure.
Interestingly enough, lowering the concentration of OPE to just 1 µg/mL had little effect
on light-activated biocidal activity, but a far larger effect on dark killing. Some level of PE
photodegradation was notable by 60 min (data not shown), which is why testing durations
were limited to 1 h, as photodegradation limits 1O2 generation.
Fig. 2B illustrates the viability of C. albicans following exposure to PPE-DABCO.
It is quite evident that, unlike EO-OPE-DABCO, its PPE counterpart is non-toxic in the
absence of light; even at a relatively high concentration of 10 µg/mL, little-to-no cell death
was observed even after 8 min of exposure to 420 nm light. After 52 min of continuous
light exposure, 10 µg/mL PPE was able to kill 99% of all C. albicans yeast cells. In
summary, we find the dark killing of the OPE to be concentration-dependent, while the
light activity is not.

Conversely, the PPE’s dark killing was not dependent on

concentration, since it failed to elicit membrane damage in that case. Biocidal activity of
PPE-DABCO is predicated on light exposure.
PPE-DABCO’s inability to kill C. albicans in the dark led us to question whether the
polymer may bind extensively to cell wall components, which could limit its ability to
access the cell membrane. We evaluated the interactions between both PEs with soluble
β-(1,3)-glucan extracted from Saccharomyces cerevisiae yeast cell walls (32).

The

structure of S. cerevisiae and C. albicans β-(1,3)-glucan is quite similar, and this
polysaccharide is an important part of Candida drug resistance and pathogenicity,
amounting to 40% of the cell wall (33). Size fractionated β-glucan (low MW = 11 kDa,
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medium MW = 150 kDa, high MW = 450 kDa) were tested (Fig. 3 A-D, Fig. S1). Excitation
and emission spectra of EO-OPE-DABCO and PPE-DABCO were evaluated in the
absence or presence of the soluble β-glucan.
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Figure 4: Excitation (A, C) and emission (B, D) spectra illustrating the interactions
between high molecular weight soluble β-glucan and EO-OPE-DABCO (top) or PPEDABCO (bottom). Dashed lines represent spectra of PE compounds alone, and solid lines
represent the spectra observed in PE/β-glucan mixtures. Inset illustrates fluorescent
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PPE-DABCO concentrated in the cell wall of a C. albicans yeast cell, as shown in Fig.
S2. Additionally, confocal microscopy images illustrate PPE-DABCO bound to glucan
microparticles. A transmitted light image (E) and reflected light image (F) are shown, with
405 nm excitation being used to generated fluorescence of bound PPE-DABCO. No
fluorescent signal is observed in the absence of PPE-DABCO (G, H).
We observed enhanced emission of both PEs upon the introduction of the high molecular
weight β-glucan, which is indicative of complexation (34). Emission enhancement is more
profound in the case of PPE-DABCO (Fig. 3 A-D), suggesting that complexation with
soluble β-glucan promotes disaggregation of the PE polymer. In addition, a small degree
of red-shifting was observed, implying that rotation of the conjugated regions of the PEs
is restricted due to complexation with soluble β-glucan (35). The complexation between
PPE-DABCO and β-glucan suggests that it may be largely sequestered in the cell wall;
such positioning promotes interaction with components of the outer cell wall, but may limit
its ability to directly disrupt the plasma membrane.
These results shed light onto the mechanisms by which EO-OPE-DABCO kills C.
albicans yeast cells (Fig. 2A; see discussion). With this in mind, the OPE became a focal
point of this study, from a biocidal perspective. Having determined that EO-OPE-DABCO
was highly effective at killing standard lab-strain C. albicans (SC5314), the question
remained whether or not its biocidal efficacy would carry over to C. albicans clinical
isolates.
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Figure 5: Susceptibility of various C. albicans clinical isolates to 10 µg/mL EO-OPEDABCO in the dark. Lab strain SC5314 is shown for reference in all cases. Strains
prefixed “TRL” are recent (circa 2015) clinical isolates obtained as described in Materials
and Methods.

Using a modified biocidal assay, six C. albicans clinical isolates were surveyed for their
susceptibility to 10 µg/mL EO-OPE-DABCO in the dark. In this instance, the cells were
stained with SYTO 9 and TO-PRO-3 before the introduction of EO-OPE-DABCO. Taking
a flow cytometry dual-fluorescent measurement of 10,000 events every minute allowed
for real-time reporting of OPE-induced membrane perturbation. The susceptibility of
clinical isolates was gauged relative to that of C. albicans SC5314, as shown in Fig. 4.
Three of the six isolates, TRL 001 (P-Value = 0.006), 051 (P-Value = 0.0013), and 057
(P-Value = 0.0003) showed significantly increased levels of OPE-resistance within 15
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minutes’ time in the form of slower kinetics of killing and higher residual viability after 15
minutes of treatment. Conversely, no OPE-resistance was observed in TRL 037, 040,
and 052.

Figure 6: Viability of C. albicans, C. glabrata, and C. parapsilosis in the presence of 10
µg/mL EO-OPE-DABCO in the dark.

Variability of susceptibility to EO-OPE-DABCO amongst clinical isolates of one species
(C. albicans) suggested that non-albicans Candida species pathogens might also exhibit
variable sensitivity to this biocide. To test this, we revised the aforementioned 15 min flow
cytometry assay to determine if EO-OPE-DABCO was more or less effective against C.
parapsilosis and C. glabrata relative to C. albicans SC5314. Fig. 5 shows similar degrees
of biocidal activity against C. albicans and C. parapsilosis, but less activity against C.
glabrata, with about 50% surviving through 15 min’ exposure. This result is consistent
with the fact that C. albicans and C. parapsilosis share a closer phylogenetic relationship
than is found between C. albicans and C. glabrata (36).
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β-glucan is highly immunogenic upon recognition by the innate immunoreceptors
Dectin-1 or Mac-1 (37).

Several prominent genera of fungal pathogens, including

Candida, are known to employ an innate immune evasive strategy of masking β-glucan
to restrict its exposure on the cell wall surface (38–41).

We hypothesize that PE

antimicrobials bound to cell wall constituents and exposed to light will generate singlet
oxygen, leading to local cell wall damage, unmasking β-glucan and increasing
immunogenicity. Using an anti-β-(1,3)-glucan primary antibody in tandem with a
secondary fluorescently-labeled antibody allowed for the comparison of β-glucan
exposure following treatment conditions: PE in the dark, PE in the light, and a 60 min
light negative control. C. albicans yeast treated with EO-OPE-DABCO in the dark, using
conditions associated with high biocidal activity (Fig. 2), exhibited no increase in β-glucan
exposure. Likewise, we observed no β-glucan unmasking with light-activated EO-OPEDABCO.

We then treated C. albicans with PPE-DABCO and observed β-glucan

exposure. PPE-DABCO clearly binds to the fungal cell wall as evidenced by strong PPEDABCO emission upon 405 nm excitation using confocal imaging (Fig. S2). In the
absence of stimulation by light, PPE-DABCO treatment results in no significant increase
in β-glucan exposure.

After illumination, PPE-DABCO treated cell walls do show

evidence of significant β-glucan unmasking (Fig. 6). These results suggested that βglucan masking in Candida cell walls is light-dependent and, presumably, mediated by
1

O2 and other ROS.
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Figure 7: Absolute β-glucan exposure of C. albicans following various treatments. βglucan exposure estimated from median fluorescence signal of AF 647. The exposure
duration of all samples was 60 min, with the exception of EO-OPE-DABCO exposure in
the light, for which the exposure duration was limited to 10 min.

Given the evidence that PPE-DABCO can increase β-glucan exposure on C. albicans
yeast, we tested whether the unmasking achieved by this treatment resulted in greater
recognition of yeasts through the β-glucan receptor Dectin-1.

HEK-293 cells were

transfected with mApple-tagged human Dectin-1a, whereby expression is sufficient to
drive phagocytosis of C. albicans yeast cells (42). Our transfection conditions resulted in
Dectin-1+ HEK-293, discriminated by positive mApple signal, and non-transfected cells,
which were negative for mApple and served as an internal control to assess Dectin-1
dependence of binding and phagocytosis. We employed a flow cytometric assay of yeast
cell binding to and internalization by HEK-293 transfectants. Yeasts were labeled with
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the pH-sensitive dye CypHer 5, which increases dramatically in emission intensity after
internalization within acidic phagosomal compartments (43, 44). The Cypher 5 signal
was used to measure binding and internalization of yeast. Flow cytometry data were
gated on HEK-293 cell-containing events for analysis, as defined by high side scatter
signal, which was significantly larger than free yeast. Yeast bound to HEK-293 cells
registered a low Cypher 5 signal. If yeasts were internalized, the CypHer 5 signal was
much higher. The percent of HEK-293 cells with yeast bound (for mApple-Dectin-1+ and
mApple-Dectin-1- cells) was determined by the percent of SSC-gated events having low
or high CypHer 5 signal. The extent of phagocytosis was assessed by the median CypHer
5 fluorescence intensity within these populations (Fig. S3).
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Figure 8: PPE-DABCO induces C. albicans yeast phagocytosis by HEK-293 cells in a
manner that requires illumination of PPE-DABCO and expression of the β-glucan receptor
Dectin-1. Prior to the addition of HEK cells, samples were first treated with 10 µg/mL
PPE-DABCO for 1 h and subsequently stained with CypHer 5 and SYTO 9. A) PPEDABCO treatment, with or without illumination, induces increased binding of C. albicans
to HEK-293 cells in a Dectin-1 independent fashion. B) Phagocytosis of C. albicans yeast
bound to HEK-293 cells requires Dectin-1 expression and is induced by light treatment of
PPE-DABCO.
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As can be seen in Fig. 7, we observe minimal binding between mApple-Dectin-1- HEK293 cells and untreated C. albicans yeast cells. Even if the HEK-293 cell has been
transfected and is expressing Dectin-1 (mApple+), β-glucan masking permits very little βglucan to be accessible at the cell wall surface for Dectin-1 binding (as seen in Fig. 6).
Conversely, PPE-treated C. albicans yeast cells bind avidly to HEK-293 cells, and this
binding is independent of excitation of PPE-DABCO or Dectin-1 expression by the HEK293 (Fig. 7A). These data suggest that the binding of PPE-DABCO to Candida cell walls
alters their surface properties in ways that promote Dectin-1 independent adhesion to
human cells, perhaps through electrostatic and/or hydrophobic mechanisms. The extent
of interaction between the yeast cell and the HEK-293 cell is not dependent on the degree
of incurred cell membrane damage, as C. albicans killed with light-activated PPE were no
more likely to bind HEK-293 cells. Despite their ability to bind HEK-293, internalization
of PPE-DABCO-treated C. albicans yeasts required Dectin-1 expression and excitation
of PPE-DABCO prior to binding (Fig. 7B). These data indicate that the β-glucan
unmasking caused by light-activation of PPE-DABCO on C. albicans cell walls results in
the biological outcome of increased Dectin-1 dependent phagocytosis.
2.4 Discussion
Cationic Phenylene Ethynylenes Exhibit Biocidal Effects against Candida Yeast
Despite their intrinsic resistance to cationic and oxidative stresses, (45, 46) C. albicans
was highly susceptible to EO-OPE-DABCO, and to a lesser extent, PPE-DABCO.
Biocidal activity of these compounds against C. albicans utilizes a dual mechanism
combining light-independent cationic stress and light-dependent oxidative stress. These
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results resemble those of previous studies, which demonstrate the effectiveness of a
dual-mechanism mode of biocidal action (47).

Unlike other broad-spectrum

antimicrobials, PEs exhibit low levels of in vitro toxicity against mammalian cells (48),
making them attractive candidates in numerous clinical applications.
Therefore, it is relevant to note that all clinical isolate strains exhibited significant
amounts of killing during a 15 min exposure to EO-OPE-DABCO. Partial resistance of
some clinical isolate strains may derive from adaptations of the pathogen to growth in the
host, which may cause changes in cell wall structure and upregulation of mechanisms
that permit growth under adverse conditions, such as leukocyte-derived ROS in the
phagosomal environment (49, 50). Previous research has also suggested a correlation
between Candida resistance to the antifungal drug amphotericin B and cell wall structure
and composition (51, 52).
While C. parapsilosis was found to be as susceptible to EO-OPE-DABCO in the
dark as C. albicans, C. glabrata displayed an inherent resistance.

Candida spp.

experience cationic stress as they interact with innate immune defenses. For example,
cationic antimicrobial peptides, such as Histatnin-5, are deployed in host defense against
Candida spp. and are thought to work by disrupting fungal plasma membrane integrity
(53). C. glabrata is noted for its resistance to killing by cationic antimicrobial peptides
relative to C. albicans and other Candida spp. pathogens (54–56). Furthermore, EOOPE-DABCO’s decreased ability to kill C. glabrata resembles the results of a previous
study, in which a 10 µg/mL concentration of the compound failed to kill 99% of S.
cerevisiae yeast, even after an hour in the light (23). Although S. cerevisiae is benign, it
is closely related to C. glabrata (32, 36). Finally, C. glabrata is also known to have robust
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antioxidative defenses that allow it to survive in the phagosome (57, 58), and may impact
its ability to resist oxidative killing by cationic phenylene ethynylenes.
Interactions with β-glucan
An interesting result of this study is that PPE-DABCO strongly associates with soluble β(1,3)-glucan (Fig. 3 C-D), which is important for structural support of the cell wall of C.
albicans (32), as well as glucan microparticles (Fig. 3 E-F). We speculate that PPEDABCO/β-glucan interaction may directly cause more global disruption to the cell wall,
and it is likely that the targeting of polymeric phenylene ethynylenes to cell wall
polysaccharides places them in an ideal position to exhibit reactive oxygen-mediated
damage to cell wall components after photoactivation.

Using transmission electron

microscopy and other techniques, Wang et al. demonstrated this behavior with PPEDABCO and Gram-negative Escherichia coli (31). However, we also note the alternative
possibility that glucan exposure upon PPE-DABCO/light treatment might require cell wall
remodeling downstream of cell wall stress responses due to ROS generated by excited
PPE-DABCO.
Conversely, the OPE appears far less prone to complexation with the soluble β(1,3)-glucan. Although this may limit the OPE’s ability to unmask mannoproteins and
reveal more β-(1,3)-glucan (Fig. 6), the lack of interaction with the glucan likely allows the
molecule to quickly penetrate the cell wall, access and damage the cell membrane.
Abundant lateral non-covalent interactions between β-glucan and PPE-DABCO may
promote PE/β-glucan complexation, analogous to the role of interpolymeric hydrogen
bonding in stabilizing lateral interactions of individual β-glucan polymers in aqueous
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solution (59, 60). PPE-DABCO is far larger than its oligomeric counterpart, and has
numerous sites where weak interactions with β-glucan polymers may form; furthermore,
extensive valency of laterally-aggregated β-glucan would make this interaction very
strong. Emission enhancement of the PE polymer (Fig. 3) resembles that of a previous
study, by which PPE-DABCO was shown to exhibit similar photophysical effects in
methanol, as opposed to water (29). Therefore, we suggest that abundant complexation
with soluble β-glucan disaggregates PPE-DABCO in aqueous buffer.
These results help in justifying the PPE’s inability to kill C. albicans in the dark.
Exhibiting a strong propensity to interact and associate with β-glucan, it is likely that PPEDABCO is limited in its ability to fully penetrate the cell wall and much of the compound
is sequestered on β-glucan in the cell wall. Given the limited radius of destruction of
singlet oxygen and the density of organic material in the cell wall capable of quenching
singlet oxygen, this association may be limiting the depth of cell wall permeation of PPEDABCO and its capacity to directly perturb the yeast’s plasma membrane, relative to EOOPE-DABCO. However, an advantage of PPE-DABCO’s ability to bind β-glucan may be
an increased specificity and targeting to the fungal pathogen’s cell wall as opposed to
host tissues, which are devoid of β-glucan. The oligomer, on the other hand, appears far
less likely to interact with β-glucan, which may allow it to permeate the fungal cell wall
more readily and better access the yeast’s plasma membrane.
PPE-DABCO Unmasks β-glucan
Furthermore, PPE-DABCO displays immunostimulatory attributes, particularly in the light.
This polymer was found to unmask the outer cell wall of C. albicans yeast cells in such a
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way that β-(1,3)-glucan could more easily be recognized and bound by pattern recognition
receptor Dectin-1. PPE-DABCO binds to yeast cell walls (Fig. S2). The chemical basis
of this binding may relate to direct interactions between PPE-DABCO and β-(1,3)-glucan,
as discussed above.

Additionally, PPE-DABCO may interact electrostatically with

anionic moieties in the outer cell wall. Ultrastructural studies have described the presence
of evenly-dispersed anionic sites on the C. albicans yeast surface (61). Also, C. albicans
N-linked mannans contain abundant oligomannose side chains attached via anionic
phosphodiester linkages that could provide sites of electrostatic binding for polycations
like PPE-DABCO (62, 63).

In either configuration, PPE-DABCO would be ideally

positioned in the outer cell wall to damage mannoproteins that are thought to provide βglucan masking. Our results suggest that merely the binding of PPE-DABCO to C.
albicans increases adherence of yeast to HEK-293 cells in a receptor-independent
fashion, suggesting that PPE-DABCO alters cell wall surface characteristics in ways that
impact interaction with host cells non-specifically (Fig. 7A). However, increases in both
β-glucan exposure and Dectin-1-dependent phagocytosis require excitation of PPEDABCO, which probably results in direct oxidative damage to the cell wall leading to βglucan unmasking. This is the first instance in which PEs have been demonstrated to
elicit immunostimulatory attributes.

Our work demonstrates that the biocidal and

immunostimulatory properties of phenylene ethynylene antimicrobials make them
promising candidates for novel antimicrobial applications to improve the health outcomes
of patients with life-threatening fungal infectious diseases.
.
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Chapter 3
Oligo-phenylene Ethynylene (OPE) Resistance in Candida glabrata
3.1 Introduction
Oligo-phenylene ethynylenes (OPEs) are a class of antimicrobial compounds with
biocidal mechanisms that include light-induced ROS generation as well as lightindependent killing (1, 2). We have found that the phenylene ethynylenes exhibit potent
antifungal activity against Candida albicans and Candida parapsilosis, two medically
significant fungal pathogens (3). In contrast, another major Candida species pathogen,
Candida glabrata, displayed intrinsically low susceptibility to OPE dark-killing, relative to
C. ablicans and C. parapsilosis (4).
The intrinsic resistance to oligo-phenylene ethynylene (OPE) seen in C. glabrata
parallels the species intrinsic resistance to other antifungals like fluconazole (5, 6). C.
glabrata’s intrinsic resistance to drugs has been attributed to the activity of efflux pumps,
which pump the drug out of the cytoplasm and reduce the cell’s exposure to antifungal
medications (7–11). We wanted to determine if efflux pumps play a role in pumping EOOPE-DABCO from the cell, effectively contributing to OPE resistance in C. glabrata. In
order to test this hypothesis, we employed a broad spectrum efflux pump inhibitor,
clorgyline, to determine whether it was possible to sensitize C. glabrata to EO-OPEDABCO biocidal activity (12).
3.2 Materials & Methods
Strains and media
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Type strains - Candida glabrata (ATCC, #2001) and Candida albicans (ATCC, #MYA2876), were grown from glycerol stocks, stored at -80 °C. Both type strains were grown
in 5 mL filtered yeast extract-peptone-dextrose (YPD) medium (Becton Dickinson), and
grown for 16 h to each exponential growth phase at 30 °C, in an orbital incubator at 300
RPM. Such growth conditions yielded yeast at the late log phase. Following a 10 minute
centrifugation at 2,900 rcf, the supernatant was replaced with sterile phosphate-buffered
saline (PBS), and subsequently vortexed. This washing step is repeated a second time
to mitigate cell debris. Cell concentration was then determined using a disposable
hemocytometer (INCYTO C-Chip; Fisher Scientific).
Clinical Isolates - Patient specimens (peripheral blood or catheter tips) were processed
by Tricore Reference Laboratories (Albuquerque, NM) and identified as C. glabrata by
FunITS at Charles River. The identified isolates were subcultured on Sabouraud agar
slants and provided to the investigators as unique strains. Isolate strains were provided
in completely deidentified form according to procedures approved by the University of
New Mexico School of Medicine Human Research Protections Office.

For biocidal

assays, clinical isolates were grown in YPD broth as described above.
S. cerevisiae strains – S. cerevisiae AD/pABC3 (control) and S. cerevisiae AD/CgCDR1
were gifts from Richard Cannon (University of Otago, New Zealand). Both strains were
grown in SD Ura medium at 30 °C for 16 hours to reach exponential growth phase.
Biocidal Testing
Biocidal experiments were carried out in either translucent or opaque 1.5 mL
microcentrifuge tubes, at cell concentrations of 5 x 106cells/mL in 1X phosphate-buffered
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saline (PBS). EO-OPE-DABCO stocks were prepared in sterile deionized water (18.2
MΩ•cm at 25 °C), and contained 0.47% dimethyl sulfoxide (by volume) to improve
solubility and minimize aggregate formation. Negative controls contained equal amounts
of dimethyl sulfoxide.
Samples were then stained with 5 µM membrane-permeable SYTO 9 and 1 µM
membrane-impermeable TO-PRO-3, both of which are nucleic acid stains. After 40 min,
samples were evaluated by flow cytometry (FACSCalibur; Becton Dickinson). At least
10,000 events were evaluated in each trial. A heat-killed sample (70 °C for 30 min) was
used to identify the fluorescence characteristics of dead cells.
Kinetics Assay - Samples were prepared and stained with SYTO 9 and TO-PRO-3, albeit
in the absence of any biocide. After a 40 min staining duration, EO-OPE-DABCO was
added (10 µg/mL final concentration); the sample was then vortexed and analyzed by
flow cytometry. Every minute, viability data was collected (again, 10,000 events/sample),
for a total of 15 minutes. It is important to note that EO-OPE-DABCO was added one
sample at a time, so that, in each case, flow cytometry readings could begin within 1 min
of the biocide’s introduction.
Extended Treatment and S. cerevisiae strains - Samples were prepared and stained with
SYTO 9 and TO-PRO-3, albeit in the absence of any biocide. After a 40 min staining
duration, EO-OPE-DABCO was added (10 µg/mL final concentration); the sample was
then vortexed and exposed to the compound in the dark at 15 min, 30 min, and 60 mins
respectively for extended treatment and 15 minutes for S. cerevisiae strains. Each sample
was analyzed by flow cytometry after the lapsed time period.
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Clorgyline pretreatment – Prepared samples at cell concentrations of 5 x 106cells/mL
were pretreated with final concentration of (100, 50, 25, 12.5, and 6.25) mM clorgyline. In
the absence of any biocide, samples were incubated for 2h with drug then stained with
SYTO 9 and TO-PRO-3 for 40 min. After the lapsed staining period, samples were subject
to EO-OPE-DABCO (10 µg/mL final concentration) for 15 min and then analyzed by flow
cytometry for an end point viability reading. Clorgyline stocks were prepared in dimethyl
sulfoxide. Negative controls contained equal amounts of dimethyl sulfoxide.
Multi-photon microscopy
Sample preparation – C. glabrata, C. albicans, and clorgyline pretreated C. glabrata cells
were seeded on glass-bottomed MatTek dishes (MatTek Corp., Ashland, MA) at a density
of 105 cells/plate in 1X phosphate-buffered saline (PBS),
Two-photon Fluorescence Imaging – Microscopy readings began within 1 min of EOOPE-DABCO introduction (1 µg/mL final concentration). EO-OPE-DABCO fluorescent
entry was monitored using multi-photon excitation on Zeiss LSM 510 Confocal
Microscope (Zeiss, Oberkochen, Germany) equipped with 63X oil immersion objective.
Samples were excited with a 20mW, 710nm laser operated at 0.5% power. A 390/40nm
BrightLine Bandpass Filter (25mm) was used to detect OPE emission. Control
experiments were conducted to minimize cellular auto fluorescence, which was not seen
until laser power was increased to 6%.
Quantitative real-time RT-PCR
This protocol was adapted from Sanguinetti et al. 2005. Total RNA was extracted from C.
glabrata (ATCC2001) and TRL026 cultures grown to the mid-exponential phase (optical
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density at 600 nm [OD600], approximately 0.6) with an RNAeasy Protect mini kit (Qiagen,
Hilden, Germany), according to the instructions of the manufacturer, by mechanical
disruption of the cells with glass beads and an RNase-free DNase treatment step. RNA
integrity was assessed by determination of the OD260/OD280 absorption ratio, and the
integrity was considered maintained if the ratio was >1.95. Quantitative expression of
the CgCDR1 gene was performed by real-time RT-PCR with a Lightcyler 96 system
(Roche Diagnostics, Indianapolis, IN).
RT-PCR was performed with a 50-μl volume containing the following reagents: 25
μl of the Platinum Quantitative RT-PCR ThermoScript reaction mixture (Invitrogen Inc.,
Milan, Italy), 1.5 U of the ThermoScript Plus/Platinum Taq mixture (Invitrogen), each
primer pair and the Taqman probe at a concentration of 5 μM, 5 μl of total RNA sample
(5, 10, 25, 50, and 100 ng), and distilled water up to the final volume.
Samples were subjected to an initial step at 52°C for 45 min for RT; 94°C for 5 min
to inactivate the ThermoScript Plus reverse transcriptase and to activate the
Platinum Taq polymerase; and 50 cycles, each of which consisted of 15 s at 94°C and 1
min at 59°C. Fluorescence data were collected during the 59°C annealing and extension
step and were analyzed with the i-Cycler iQ software. Each reaction was run in duplicate.
3.3 Results
Recent research has explored the use of phenylene ethynylenes as novel antifungals,
Candida glabrata displayed intrinsically low-susceptibility to oligo-phenylene ethynylene
(OPE) as comparted to C. ablicans and C. parapsilosis (4). A series of experiments were
conducted to elucidate the mechanism of OPE-resistance in C. glabrata. The mechanism
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of action for EO-OPE-DABCO differs depending on the presence or absence of light. The
subsequent studies were performed in dark; the compound was not subject to light
irradiation.
It was important to replicate previously published results and validate that EO-OPEDABCO was indeed more effective against type strain C. albicans (SC5314) than C.
glabrata (ATCC2001).
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Figure 1: Viability of C. albicans and C. glabrata in the presence of 10 µg/mL EO-OPEDABCO in the dark.
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Figure 1 shows that C. glabrata is less susceptible to EO-OPE-DABCO after 15 minutes
of exposure. The cells were stained with SYTO 9 and TO-PRO-3 before the introduction
of EO-OPE-DABCO. Taking a flow cytometry dual-fluorescent measurement of 10,000
events every minute allowed for real-time reporting of OPE-induced membrane
perturbation. These results were consistent with previously published results that showed
EO-OPE-DABCO biocidal activity is more effective against C. albicans.
Using a modified biocidal assay, cell exposure to EO-OPE-DABCO was varied to
determine the degree of OPE resistance C. glabrata displayed. In addition to the custom
15 minute viability reading, readings after 30 min and 60 min OPE exposure were tested.
Increasing cell exposure to the compound did not increase C. glabrata susceptibility
relative to C. albicans (SC5314), as shown in Fig. 2.
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Figure 2: Viability of C. albicans and C. glabrata after treatment with of 10 µg/mL EOOPE-DABCO in the dark at 15 min, 30 min, and 60 min.

Additionally, Figure 2 illustrates that after increasing exposure time four fold, EO-OPEDABCO was unable to induce complete C. glabrata cell death.
While EO-OPE-DABCO was highly effective at killing the standard type strain C. albicans
(SC5314) and C. albicans clinical isolates, we sought to determine whether C. glabrata
clinical isolates were also less susceptible to OPE. From an extensive clinical isolate
library, six C. glabrata clinical isolates were surveyed for their susceptibility to 10 µg/mL
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EO-OPE-DABCO in the dark. The susceptibility of clinical isolates was gauged relative to
that of C. glabrata ATCC2001, as shown in Fig. 3.

Figure 3: Susceptibility of various C. glabrata clinical isolates to 10 µg/mL EO-OPEDABCO in the dark. Lab strain ATCC2001 is shown for reference in all cases. Strains
prefixed “TRL” are recent (circa 2015) clinical isolates obtained as described in
Materials and Methods.

These results consistently show that C. glabrata is able to withstand the biocidal activity
of EO-OPE-DABCO as compared to other tested pathogens (13–17).
The intrinsic resistance to oligo-phenylene ethynylene (OPE) seen in C. glabrata parallels
the species intrinsic resistance to other antifungals, like fluconazole, which can be
mediated by efflux pumps. We employed a broad spectrum efflux pump inhibitor,
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clorgyline (12), to determine whether it was possible to sensitize C. glabrata to EO-OPEDABCO biocidal activity. Before exposure to EO-OPE-DABCO, cells were incubated with
clorgyline at varying concentrations. It was important to determine whether the effect of
clorgyline was synergistic or additive. Using the proper dimethyl sulfoxide and clorgyline
controls, a synergistic index was calculated. The index was calculated using the equation
(Fig. 4). A value of one would indicate an additive effect of both compounds. Figure 4A
illustrates the effect various concentrations of clorgyline treatment had on OPE killing. At
25 ug/mL, clorgyline was able to most effectively sensitize yeast C. glabrata cells to OPE
killing, the calculated synergistic index at this concentration was 2.24.
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Figure 4[A]. Synergistic effects of clorgyline at varying concentrations when C.
glabrata (ATCC2001) is treated with 10 μg/mL EO-OPE-DABCO. The synergistic index
was calculated using the equation above, a value of 1 indicates a purely additive killing
effect of clorgyline and EO-OPE-DABCO. Figure 4[B]. Flow cytometry readings for
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three treatments are shown (25ug/mL clorgyline, 10ug/mL OPE, and combined
treatment of 25ug/mL clorgyline and 10ug/mL OPE). The events in the green gate are
live cells and the events in the red gate are dead cells. Figure 4[C]. The viability of C.
glabrata (ATCC2001) cells after each specified treatment is shown. Treating cells with
25ug/mL clorgyline and then 10ug/mL OPE induced complete cell death.

At this concentration cell death by clorgyline was simultaneously minimized while cell
death by OPE was maximized. This effect is most clearly illustrated in Figure 4B. The flow
cytometry contour plots illustrate the synergistic effect between 25 ug/mL clorgyline with
10 ug/mL EO-OPE-DABCO. The flow cytometry dual-fluorescent assay, shows that most
events after pretreatment with 25 ug/mL clorgyline appeared in the dead gate, as
measured by TO-PRO-3 perturbation (Fig. 4B). At this concentration of clorgyline, C.
glabrata cells are sensitized to OPE killing and almost complete cell death is induced (Fig.
4C).
EO-OPE-DABCO is fluorescent when excited with 355nm light (1, 18, 2). This
characteristic allowed us the capacity to directly measure cytoplasmic concentration of
OPE in the yeast cells using two-photon microscopy (Figure 5). It was important to
observe cytoplasmic entry of the compounds in order to understand the role efflux pumps
might play in reducing sensitivity to EO-OPE-DABCO in C. glabrata on the cellular level.
We hypothesized that there would be lower cytoplasmic concentration of EO-OPEDABCO in C. glabrata relative to C. albicans. Subsequently we expected to observe an
increase in cytoplasmic concentration of OPE in C. glabrata after application of clorgyline.
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Figure 5. Two-photon microscopy images show the intracellular accumulation of 10
μg/mL EO-OPE-DABCO over the course of 15 minutes.

Using two-photon imaging provided a way to fluorescently track the kinetic entry of OPE
into the yeast cells through the 15 minute time course. The images taken at different time
points show the accumulation of OPE in the cell as depicted by increasing fluorescence
(Figure 5).
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Figure 6. The OPE entry kinetics were monitored using two-photon microscopy in C.
albicans (SC5314) cells, C. glabrata (ATCC2001) cells, and 25 ug/mL clorgyline
pretreated C. glabrata (ATCC2001) cells over the course of 15 mintues.

We hypothesized that there would be lower cytoplasmic concentration of EO-OPEDABCO in C. glabrata relative to C. albicans. The compound was introduced to the yeast
cells within in a minute of imaging. The kinetic entry of OPE was tracked by measuring
mean fluorescent intensity every minute across 60 cells. We observed slower
accumulation of OPE in C. glabrata (Figure 5 and Figure 6). Additionally, pretreatment of
C. glabrata with clorgyline increased OPE accumulation closer to C. albicans’ levels. Both
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flow cytometric assays and two-photon imaging suggest that efflux pumps might play a
role in regulating OPE-resitance in C. glabrata.

Viability

100%

50%

0%
AD/CgCDR1

AD/pABC3

Figure 7. Treatment of Saccharomyces cerevisiae AD/pABC3 and AD/CgCDR1 mutant
strains with 10 μg/mL EO-OPE-DABCO in the dark.

The effect of clorgyline to enhance OPE killing led us to question what specific efflux
pump was being targeted. Clorgyline has been identified as a broad spectrum pump
inhibitor and was specifically able to reverse fluconazole-resistance in a S. cerevisiae
mutant that overly expressed efflux pump CgCDR1.

We tested the S. cerevisiae

AD/pABC3 (control) and S. cerevisiae AD/CgCDR1 (over-expression) strains to see if the
over-expression of CgCDR1 conferred OPE-resistance. When treated with 10ug/mL EOOPE-DABCO, the S. cerevisiae AD/CgCDR1 was no more resistant to the compound
than the control S. cerevisiae AD/pABC3 or C. glabrata (ATCC2001). These results
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indicate that clorgyline does not act on CgCDR1 in a manner that contributes to OPEresistance.

Figure 8. Fold induction difference between TRL 026 and ATCC 2001 for CgCDR1 for
different amounts of extract RNA. The fold induction difference does exceed a value of
1.10.
Consistent with these results, we found no upregulation of CgCDR1 at the message level
in one of the more resistant isolates, TRL026, as compare to the type strain (ATCC2001).
This was determined by qRT-PCR (Figure 8).
3.4 Discussion
Despite the effective biocidal activity of EO-OPE-DABCO against C. albicans in the dark,
C. glabrata possess an intrinsic resistance to the compound (4). The light-independent
mechanism of killing is not effective enough to induce complete cell death of C. glabrata
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even after prolonged exposure to the compound (Figure 1 and Figure 2). The intrinsic
resistance to OPE seen in C. glabrata is unique in comparison to other Candida species
tested, but consistent with its response to other antifungals. Specifically, C. glabrata
possess significant healthcare threats because of its characteristic intrinsic and acquired
resistance to common antifungals such as azoles (19–21).
While the inhibitory effects of clorgyline are considered broad spectrum, our data
suggests that CgCDR1, a major efflux pump, is not implicated in OPE sensitivity when
heterologously expressed in S. cerevisiae (8, 12, 22). The target of clorgyline in
sensitizing C. glabrata to OPE killing needs to be further studied. Clorgyline was initially
marketed as an antidepressant, inhibiting cytochrome P450 monoamine oxidase A, a
member of the flavin monoxidase family (23). Yeast species are known to have members
of this family of enzymes. In C. glabrata, a well characterized cytochrome P450 is
lanoserol 14-alpha-demethylase encoded by ERG11, the target of fluconazole. ERG11 is
known be involved in ergosterol synthesis and ergosterol content affects membrane
fluidity in fungi (24). Consequently, clorgyline might act on this P450 enzyme affecting the
plasma membrane environment and other membrane proteins such as efflux pumps.
The differential OPE sensitivity between Candida species might be attributed to
lipid composition. Previous work has shown that drug resistance can arise from an altered
membrane sterol pattern in yeast (25, 26). Similarly, the lipid composition in Candida
glabrata might better facilitate membrane perturbation by the quaternary ammonium side
groups on EO-OPE-DABCO.

Model membranes, mimicking those of bacterial

membranes and mammalian membranes showed significant membrane perturbation by
OPE against only against bacterial mimic membranes (27).
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In addition, our results indicate that C. glabrata is not killed much more by
extending the EO-OPE-DABCO dark treatment significantly beyond 15minutes (Figure
2). The target of EO-OPE-DABCO membrane disruption could be intracellular organelles,
like the vacuole and mitochondria. Disruption of these membranes and their associated
proton gradients would be regulated by intracellular EO-OPE-DABCO concentration,
which is in turn related by the balance between diffusion of EO-OPE-DABCO into the cell
and pumping of EO-OPE-DABCO back out. Our results indicate that when we treat the
cells with clorgyline, killing by EO-OPE-DABCO is increased and intracellular
concentration is increased (Figure 4 and 6). Increasing intracellular concentration targets
intracellular organelles and results in the loss of membrane integrity measure by TOPRO-3 uptake. Future work would involve checking whether treatment with EO-OPEDABCO damages the ability of vacuolar and/or mitochondrial membranes to maintain
their proton gradient. We would argue that intracellular membranes may be the actual
target of EO-OPE-DABCO. It is suggestive that yeast regulates its susceptibility to the
antimicrobial by protecting intracellular membrane by keeping the intracellular
antimicrobial concentration low enough to protect plasma membrane integrity.
Understanding the mechanisms of OPE resistance of C. glabrata is clinically
significant because they will allow the development of novel strategies to prevent and
treat infection by this emerging pathogen. While PE’s possess a dual-mechanism of
action, the light-independent mechanism of killing of OPE is more practical for clinical
use. The application of clorgyline as an avenue to reverse OPE-resistance in C. glabrata
confers a clinical benefit for the use of EO-OPE-DABCO as a future antifungal.
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Chapter 4
Conclusions and Recommendations for Future Work
4.1 Efficacy of PPE-DABCO and EO-OPE-DABCO against Candida spp. hyphae
and biofilms
In Chapter 2, the efficacy of PPE-DABCO and EO-OPE-DABCO as antifungals was
examined. These experiments were however limited to yeast cells. It is important to
further extend testing these compounds against C. albicans hyphae and biofilms,
because most candidiasis infections persist as biofilms (1–4) . Preliminary studies have
been done assessing the effectiveness of EO-OPE-DABCO as C. albicans hyphae
(Figure 1). Using SYTO9 and TO-PRO-3 viability staining (Chapter 1), the fluorescent
confocal images show that OPE is able effective against C. albicans hyphae as assessed
by TO-PRO-3 uptake (red). The quantification of total hyphal cell death is something that
needs further work.
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Figure 9: C. albicans hyphae treatment with 10ug/mL of EO-OPE-DABCO in the dark for
60 minutes
New experiments will require treating C. albicans hyphae and biofilms with both
PPE-DABCO and EO-OPE-DABCO in the dark and when irradiated by the appropriate
wavelength. Viability would be assessed through TO-PRO-3 uptake. I would expect to
see more efficient cell killing with OPE because of its dual capabilities to kill effectively in
the dark and in the light. Since, PPE-DABCO is more likely to associate with components
in extracellular matrix such as B-glucan (Chapter 1, Figure 6), I would expect to see less
efficient killing (5). In turn, PPE-DABCO might get stuck in the biofilm matrix before being
able to induce cell damage.
4.2 Determining efflux pumps involved in OPE-resistance in Candida glabrata
In Chapter 3, the intrinsic OPE-resistance seen in C. glabrata was investigated.
The experiments performed were part of an inhibitory study that suggest clorgyline is
effective at improving the efficacy of OPE against C. glabrata. There is future work needed
to determine the mechanism behind this resistance in C. glabrata. A major efflux pump,
CgCDR1, seems to not impact OPE sensitivity when heterologously expressed in S.
cerevisiae. While this pump cannot be implicated in OPE-resistance in C. glabrata, other
pumps related to multidrug resistance in C. glabrata such as CgCdr2 (Pdh1), and CgSnq2
have yet to be tested (6, 7). As a broad-spectrum pump inhibitor, it is possible that
clorgyline could be acting on these pumps. Testing S. cerevisiae strains that over-express
these pumps and performing qRT-PCR on especially OPE resistant clinical isolates might
yield insight on how C. glabrata is able to resist OPE killing on a molecular level.
Additionally, clorgyline effects both ABC and MFS transporters, which have different

61

mechanisms of pumping (8). There is little known about MFS transporters in C. glabrata
and their impact on drug resistance. With further studies, it is possible that OPE resistance
seen in C. glabrata could also be facilitated by MFS transporters as well.
4.3 Investigating clorgyline’s mechanism of action in Candida glabrata
The mechanism of action of clorgyline might involve more than efflux regulation
but also the regulation of membrane lipid composition. If clorgyline is inhibiting ERG11, a
cytochrome P450 in C. glabrata (7, 9), it could be reducing ergosterol concentration in the
membrane, but not enough to produce notable antifungal effects. This would be similar
to the effect of fluconazole on ERG11. It could also be indirectly targeting the sterol
transporter CgAUS1 that has shown to protect cells against azoles in the presence of
serum. CgAUS1 gene product functions as a sterol transporter that ameliorates the
growth inhibition caused by the loss of ERG9 expression or fluconazole-mediated
inhibition of Erg11p (10). While efflux regulation is part of OPE-resistance in C. glabrata,
the alternative hypothesis might be clorgyline increases susceptibility of C. glabrata to
OPE by lowering the plasma membrane ergosterol content, which makes the membrane
more susceptible to disruption by OPE. One direct approach to examine this would be to
make vesicles from pure phospholipids and ergosterol, vary the amount of ergosterol and
see if it changes sensitivity to OPE.
4.4 Potential applications of phenylene ethynylenes
Some anti-fungal medical applications envisioned for phenylene ethynylenes
concern treatment of medical devices or topical applications in wound care. For instance,
prevention of catheter infections using improved antimicrobial materials or preventive
device treatment regimens could save lives, improve quality of life and reduce costs
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associated with treating catheter-associated infections.

However, providing light to

activate phenylene ethynylenes in the catheter context is an important challenge. First,
we showed that EO-OPE-DABCO has strong biocidal activity against C. albicans, even
without light activation, so it is possible that this compound could be used in antifungal
lock solutions even without illumination. Second, central venous catheters are susceptible
to contamination via their hubs and injection ports. These device parts are external and
accessible for illumination by external sources or integrated LED source. The port and
hub lumen could be regularly filled with a phenylene ethynylene antimicrobial and
subjected to light induced disinfection as part of a routine infection prevention program.
Third, phenylene ethynylene compounds could be grafted to external medical device
materials (e.g., central venous catheter hubs, ports and tubes) to incorporate surfaces
that could be regularly disinfected by application of light. In addition, phenylene
ethynylenes could find medical use in the area of wound care as topically applied
antimicrobials and by incorporation into wound dressings. In this setting, light activation
could be applied manually from external sources during dressing changes, or in a more
automated fashion from an integrated dressing LED light source, to prevent
contamination of the wound. Additional costs associated with the use of antimicrobial
catheter treatments and associated illumination systems would be offset by prevention of
the substantial costs associated with treating catheter-associated infections, as well as
by improvements in patient morbidity and mortality.
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